Contribution
My Lords, this has been an important debate on a subject that too often generates more heat than light. I thank noble Lords who have spoken for the tone in which the debate has been held. In particular, I thank the noble Baroness, Lady Cass, whose review has done more than anything else to move the debate from slogans to trying to get us to follow the evidence.
We should start with where the law stands today on puberty blockers, because it matters. The sale and supply of in-person puberty blockers to under-18s for gender dysphoria outside a clinical trial has been banned indefinitely since the start of 2025 and the PATHWAYS trial has now been approved by the regulator. In March this year, NHS England paused new prescriptions of cross-sex hormones for under-18s. In February, the Government laid an order under the Gender Recognition Act so that the data linkage study can lawfully go ahead. A great deal has changed, but this Bill will abolish NHS England and almost every one of those commitments lives in NHS England’s policy documents, not in law. The question for the Committee is simple: when that body goes, who will hold the pen and who will answer to Parliament? I would welcome the Minister’s answer to that.
These Benches—as I am sure all Benches do— approach this from three principles: the evidence should lead; every person who walks into a clinic, whether they are seeking to transition, to explore or to detransition, deserves dignity and proper care; and people’s privacy must be protected. I do not believe that those principles are in conflict, as the review of the noble Baroness, Lady Cass, showed. They all belong together.
On Amendment 75, the Levy review found that waits for a first appointment were heading towards 15 years and that clinics could not say whether the treatment they gave had worked, because outcomes were not systematically recorded. A national specification, national commissioning, outcome data and a single waiting list are not an attack on anybody; they are what you would expect of any other specialised service. As the noble Lord, Lord Hunt, said, this is probably not the responsibility of an ICB. Can the Minister tell us who will be accountable for each of Dr Levy’s 20 recommendations once NHS England has gone? On the list of specialised commissioning, do the Government expect this to be a national commissioning service or a local ICB commissioning service?
I turn to Amendment 275 on the data duty. The noble Baroness, Lady Davies, raised some important points, but, as my noble friend Lady Barker said, we have to consider the context of what is happening in looking at a data duty. Six of the seven adult clinics did not give data to the Cass review. This is not acceptable for any public body or any publicly funded service. It has left us with a bit of a gap for young people in terms of what happened to those who went before them. A legal duty may be justified, but, because this is some of the most sensitive data that the NHS holds, the safeguards matter—ethical approval, pseudonymisation and use for that study only. Can the Minister say whether the February order does the job for the Cass study? If so, will such orders extend that same protection to other approved studies? There is an issue, as my noble friend Lady Barker said, about the time limit on collecting such data.
On Amendment 276, people who detransition have often been invisible—unwelcome in some gender services and unknown to everybody else. They deserve care without judgment. The Government have told this House that consultation on a service specification will not come until autumn 2027. A statutory deadline and anonymised annual reporting would help us learn. Learning is not blaming, and that is the point. Is that timeline still applicable?
In relation to Amendment 279QP, I sit on the Draft Conversion Practices Bill Joint Committee. I will not prejudge its work, but it is grappling with and well aware of some of the issues that noble Lords are talking about. Clinicians must be confident that they can treat a young person’s autism, anxiety or trauma and explore their distress without presuming an outcome and without fear that this will be called a conversion practice or that they will be held to a criminal charge. Equally, genuinely coercive practices must be outlawed, and proposed new subsection (5) in the amendment recognises that. Getting that line right matters to everybody, and I would welcome the Minister’s views on how this amendment fits with the draft Bill. Does she feel that it would be useful or not in terms of the issues that noble Lords have raised?
Finally, I turn to Amendment 279QQ. There seems to be an inconsistency in the current position. If the evidence is strong enough for the NHS not to start a 16 year-old on these hormones, how do the Government explain that the same young person can obtain them from a private or overseas prescriber online, outside of any specialist assessment? Closing that gap may be a safeguarding issue, so I would welcome the Minister’s view.
The review of the noble Baroness, Lady Cass, asked us to remember that these are children, young people and adults who deserve the same standard of evidence-based care as everyone else. That is not a position on either side of a deeply divided or polarised argument; it is simply good medicine. I look forward to the Minister’s reply.